Abiomed AbioCor Proxy Consent Policy Will Hasten Pace Of Trial Enrollment
This article was originally published in The Gray Sheet
Executive Summary
Abiomed's decision to allow relatives to provide informed consent for patient participation in the AbioCor artificial heart trial should ensure a greater number of patients will be eligible for implantation
You may also be interested in...
Abiomed Pumps Up Temporary Heart Assist Offerings With AB5000 Ventricle
Abiomed expects FDA's Sept. 25 approval of a PMA supplement for its AB5000 Ventricle biventricular cardiac assist system to help reinvigorate stagnant temporary cardiac assist capital equipment sales
Abiomed Pumps Up Temporary Heart Assist Offerings With AB5000 Ventricle
Abiomed expects FDA's Sept. 25 approval of a PMA supplement for its AB5000 Ventricle biventricular cardiac assist system to help reinvigorate stagnant temporary cardiac assist capital equipment sales
LVAD Market Estimated At 30,000, Thoratec Still Awaiting Coverage Decision
The potential U.S. market for artificial replacement hearts, assuming a two-year device lifespan, is about 36,000 patients per year, according to Abiomed